These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 24425059)

  • 1. Mechanism of a decrease in potency for the recombinant influenza A virus hemagglutinin H3 antigen during storage.
    Hickey JM; Holtz KM; Manikwar P; Joshi SB; McPherson CE; Buckland B; Srivastava IK; Middaugh CR; Volkin DB
    J Pharm Sci; 2014 Mar; 103(3):821-7. PubMed ID: 24425059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modifications of cysteine residues in the transmembrane and cytoplasmic domains of a recombinant hemagglutinin protein prevent cross-linked multimer formation and potency loss.
    Holtz KM; Robinson PS; Matthews EE; Hashimoto Y; McPherson CE; Khramtsov N; Reifler MJ; Meghrous J; Rhodes DG; Cox MM; Srivastava IK
    BMC Biotechnol; 2014 Dec; 14():111. PubMed ID: 25540031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved stability of recombinant hemagglutinin using a formulation containing sodium thioglycolate.
    Rhodes DG; Holtz K; Robinson P; Wang K; McPherson CE; Cox MM; Srivastava IK
    Vaccine; 2015 Nov; 33(44):6011-6. PubMed ID: 26409814
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    An Y; Parsons LM; Jankowska E; Melnyk D; Joshi M; Cipollo JF
    J Virol; 2019 Jan; 93(2):. PubMed ID: 30355697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulation development of a plant-derived H1N1 influenza vaccine containing purified recombinant hemagglutinin antigen.
    Iyer V; Liyanage MR; Shoji Y; Chichester JA; Jones RM; Yusibov V; Joshi SB; Middaugh CR
    Hum Vaccin Immunother; 2012 Apr; 8(4):453-64. PubMed ID: 22370514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inactivated influenza vaccine stress can affect in vitro potency assay relationship to immunogenicity.
    Wen Y; Palladino G; Xie Y; Ferrari A; Settembre EC
    Vaccine; 2018 May; 36(21):3010-3017. PubMed ID: 29680201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pandemic influenza vaccine: characterization of A/California/07/2009 (H1N1) recombinant hemagglutinin protein and insights into H1N1 antigen stability.
    Feshchenko E; Rhodes DG; Felberbaum R; McPherson C; Rininger JA; Post P; Cox MM
    BMC Biotechnol; 2012 Oct; 12():77. PubMed ID: 23110350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of recombinant hemagglutinin proteins as alternative antigen standards for pandemic influenza vaccines.
    Choi Y; Kwon SY; Oh HJ; Shim S; Chang S; Chung HJ; Kim DK; Park Y; Lee Y
    Biotechnol Lett; 2017 Sep; 39(9):1375-1380. PubMed ID: 28612264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.
    King JC; Cox MM; Reisinger K; Hedrick J; Graham I; Patriarca P
    Vaccine; 2009 Nov; 27(47):6589-94. PubMed ID: 19716456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An ELISA-based assay for determining haemagglutinin potency in egg, cell, or recombinant protein derived influenza vaccines.
    Bodle J; Vandenberg K; Laurie K; Barr IG; Zhang Y; Rockman S
    Front Immunol; 2023; 14():1147028. PubMed ID: 37033922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
    Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Collaborative studies on the development of national reference standards for potency determination of H7N9 influenza vaccine.
    Li C; Xu K; Hashem A; Shao M; Liu S; Zou Y; Gao Q; Zhang Y; Yuan L; Xu M; Li X; Wang J
    Hum Vaccin Immunother; 2015; 11(6):1351-6. PubMed ID: 25970793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Egg- or cell culture-derived hemagglutinin mutations impair virus stability and antigen content of inactivated influenza vaccines.
    Nakowitsch S; Waltenberger AM; Wressnigg N; Ferstl N; Triendl A; Kiefmann B; Montomoli E; Lapini G; Sergeeva M; Muster T; Romanova JR
    Biotechnol J; 2014 Mar; 9(3):405-14. PubMed ID: 24323790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fabrication of cell culture-derived influenza vaccine dissolvable microstructures and evaluation of immunogenicity in guinea pigs.
    Bonificio A; Ghartey-Tagoe E; Gallorini S; Baudner B; Chen G; Singh P; O'Hagan DT; Kommareddy S
    Vaccine; 2015 Jun; 33(25):2930-8. PubMed ID: 25930118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conformationally selective biophysical assay for influenza vaccine potency determination.
    Wen Y; Han L; Palladino G; Ferrari A; Xie Y; Carfi A; Dormitzer PR; Settembre EC
    Vaccine; 2015 Oct; 33(41):5342-5349. PubMed ID: 26348403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formulation Studies During Preclinical Development of Influenza Hemagglutinin and Virus-Like Particle Vaccine Candidates.
    Wahome N; Hickey JM; Volkin DB; Middaugh CR
    Methods Mol Biol; 2016; 1404():393-421. PubMed ID: 27076313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VaxArray assessment of influenza split vaccine potency and stability.
    Kuck LR; Saye S; Loob S; Roth-Eichhorn S; Byrne-Nash R; Rowlen KL
    Vaccine; 2017 Apr; 35(15):1918-1925. PubMed ID: 28262335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissolved carbon dioxide determines the productivity of a recombinant hemagglutinin component of an influenza vaccine produced by insect cells.
    Meghrous J; Khramtsov N; Buckland BC; Cox MM; Palomares LA; Srivastava IK
    Biotechnol Bioeng; 2015 Nov; 112(11):2267-75. PubMed ID: 25943562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel antibody-independent receptor-binding SPR-based assay for rapid measurement of influenza vaccine potency.
    Khurana S; King LR; Manischewitz J; Coyle EM; Golding H
    Vaccine; 2014 Apr; 32(19):2188-97. PubMed ID: 24613520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An immuno-assay to quantify influenza virus hemagglutinin with correctly folded stalk domains in vaccine preparations.
    Rajendran M; Sun W; Comella P; Nachbagauer R; Wohlbold TJ; Amanat F; Kirkpatrick E; Palese P; Krammer F
    PLoS One; 2018; 13(4):e0194830. PubMed ID: 29617394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.